Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock

19 Mar 2026, 21:00 by Scott Moore · The Cerbat Gem

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) insider Noah Berkowitz sold 6,435 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $11.10, for a total value of $71,428.50. Following the transaction, the insider directly owned 202,503 shares of the company’s stock, valued at $2,247,783.30. This trade represents a 3.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Noah Berkowitz also recently made the following trade(s):

On Friday, February 13th, Noah Berkowitz sold 5,685 shares of Arvinas stock. The stock was sold at an average price of $11.89, for a total value of $67,594.65.

Arvinas Trading Up 2.6%

Shares of Arvinas stock traded up $0.28 on Thursday, reaching $11.17. 1,230,582 shares of the company were exchanged, compared to its average volume of 907,784. Arvinas, Inc. has a one year low of $5.90 and a one year high of $14.51. The company has a market capitalization of $714.43 million, a price-to-earnings ratio of -8.73 and a beta of 1.87. The company has a 50-day moving average of $12.72 and a 200 day moving average of $11.13.

Arvinas (NASDAQ:ARVN – Get Free Report) last released its earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.55). The firm had revenue of $9.50 million during the quarter, compared to the consensus estimate of $37.26 million. Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. Arvinas’s quarterly revenue was down 84.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.63) earnings per share. Analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Hedge Funds Weigh In On Arvinas

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Campbell & CO Investment Adviser LLC grew its stake in Arvinas by 307.7% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 223,576 shares of the company’s stock valued at $1,905,000 after buying an additional 168,744 shares during the last quarter. Nordea Investment Management AB lifted its position in Arvinas by 28.7% during the third quarter. Nordea Investment Management AB now owns 557,742 shares of the company’s stock worth $4,730,000 after acquiring an additional 124,254 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Arvinas during the second quarter worth approximately $390,000. 22NW LP bought a new stake in shares of Arvinas during the second quarter worth approximately $3,044,000. Finally, Velan Capital Investment Management LP bought a new stake in shares of Arvinas during the second quarter worth approximately $3,680,000. 95.19% of the stock is owned by institutional investors.

More Arvinas News

Here are the key news stories impacting Arvinas this week:

Positive Sentiment: Positive Phase 1 data for ARV-102 showed >50% LRRK2 degradation in CSF after 28 days and reductions in endolysosomal and neuroinflammatory biomarkers—data that de‑risks the Parkinson’s program and increases the drug’s clinical value. Arvinas Announces Positive Phase 1 Data for ARV-102
Positive Sentiment: Citigroup raised its price target from $18 to $21 and initiated/maintained a Buy rating—an analyst upgrade that implies a large upside and can attract momentum investors. Benzinga
Positive Sentiment: BTIG bumped its target from $14 to $16 and keeps a Buy rating, providing additional brokerage support for the shares and reinforcing the sentiment shift after the clinical news. Benzinga
Neutral Sentiment: Short-interest reports for mid‑March show anomalous zero/NaN values and a 0.0 days-to-cover figure—data appears unreliable or miscoded and currently offers no clear sign of increased short pressure. Investors should watch for corrected filings for a clearer picture. TipRanks / Short Interest Note

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ARVN shares. BTIG Research boosted their price objective on shares of Arvinas from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday. Citigroup raised their target price on shares of Arvinas from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday. Truist Financial set a $10.00 price target on Arvinas in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a research report on Monday, December 22nd. Finally, Piper Sandler restated an “overweight” rating and issued a $20.00 price objective (up from $16.00) on shares of Arvinas in a research note on Wednesday, February 25th. Ten analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $13.88.

Check Out Our Latest Research Report on Arvinas

About Arvinas

(Get Free Report)

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.